This study focused on the preparation of docosahexaenoic acid(DHA) and eicosapentaenoic acid(EPA)enriched-triacylglycerols by enzymatic interesterification using tuna oil and capric acid. The content of DHA+EPA is 26....This study focused on the preparation of docosahexaenoic acid(DHA) and eicosapentaenoic acid(EPA)enriched-triacylglycerols by enzymatic interesterification using tuna oil and capric acid. The content of DHA+EPA is 26.86% in the tuna oil used in this study. A response surface methodology(RSM) was used to optimize the reaction parameters(reaction temperature, substrate molar ratio, enzyme amount and reaction time), and the optimized conditions were determined to be: reaction temperature 58℃, substrate molar ratio(capric acid : tuna oil) 4:1, enzyme amount 4%, and reaction time 7.5 h. Under the optimized conditions, the content of DHA+EPA in the glycerides was 40.03%, which is 13.17% higher than that in raw tuna oil. In addition,the MLM-type structured lipids containing medium chain fatty acids(capric acid) at positions sn-1,3 and a long chain fatty acid(DHA/EPA) at the position sn-2 may have many health benefits for humans.展开更多
<strong>Background:</strong> <span><span style="font-family:Verdana;">Omega-3 polyunsaturated fatty acids (PUFAs) have some protective benefits for patients with coronary artery and c...<strong>Background:</strong> <span><span style="font-family:Verdana;">Omega-3 polyunsaturated fatty acids (PUFAs) have some protective benefits for patients with coronary artery and cerebrovascular diseases. Eicosapentaenoic acid (EPA) drugs are prescribed as branded (B: EPADEL</span><sup><span style="font-family:Verdana;"><span style="color:#4F4F4F;font-family:-apple-system, " font-size:14px;white-space:normal;background-color:#ffffff;"="">?</span></span></sup><span style="font-family:Verdana;">) or generic products but no data exist concerning the differences in treatment outcomes between these products. </span><b><span style="font-family:Verdana;">Methods and Results: </span></b><span style="font-family:Verdana;">We investigated the differences in the serum levels of EPA, docosahexaenoic acid (DHA) and arachidonic acid (AA), and the EPA/AA ratios through blood sampling six months after daily administration of 1800 mg of EPADEL</span><sup><span style="font-family:Verdana;"><span style="color:#4F4F4F;font-family:-apple-system, " font-size:14px;white-space:normal;background-color:#ffffff;"="">?</span></span></sup><span style="font-family:Verdana;"> and a generic EPA drug was initiated for 96 patients with cardiovascular diseases. All patients received these PUFA treatments while continuing with baseline therapy. After 6 months of administration, EPADEL</span><sup><span style="font-family:Verdana;"><span style="color:#4F4F4F;font-family:-apple-system, " font-size:14px;white-space:normal;background-color:#ffffff;"="">?</span></span></sup><span style="font-family:Verdana;"> produced better results than the generic (G) product (EPA;baseline: 59.4 ± 25.5 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B: 215.5 ± 58.8 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, G: 199.7 ± 63.8 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B vs G, p < 0.0005;AA;baseline: 197.4 ± 44.6 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B: 158.3 ± 36.3 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, G: 163.6 ± 38.9 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B vs G, p < 0.02, as mean ± SD). </span><b><span style="font-family:Verdana;">Conclusions</span></b></span><b><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> There were clear differences between EPA branded and the generic products. Further study is required to determine whether the benefits from the branded product justify the higher price compared to the generic drug cost.</span>展开更多
文摘This study focused on the preparation of docosahexaenoic acid(DHA) and eicosapentaenoic acid(EPA)enriched-triacylglycerols by enzymatic interesterification using tuna oil and capric acid. The content of DHA+EPA is 26.86% in the tuna oil used in this study. A response surface methodology(RSM) was used to optimize the reaction parameters(reaction temperature, substrate molar ratio, enzyme amount and reaction time), and the optimized conditions were determined to be: reaction temperature 58℃, substrate molar ratio(capric acid : tuna oil) 4:1, enzyme amount 4%, and reaction time 7.5 h. Under the optimized conditions, the content of DHA+EPA in the glycerides was 40.03%, which is 13.17% higher than that in raw tuna oil. In addition,the MLM-type structured lipids containing medium chain fatty acids(capric acid) at positions sn-1,3 and a long chain fatty acid(DHA/EPA) at the position sn-2 may have many health benefits for humans.
文摘<strong>Background:</strong> <span><span style="font-family:Verdana;">Omega-3 polyunsaturated fatty acids (PUFAs) have some protective benefits for patients with coronary artery and cerebrovascular diseases. Eicosapentaenoic acid (EPA) drugs are prescribed as branded (B: EPADEL</span><sup><span style="font-family:Verdana;"><span style="color:#4F4F4F;font-family:-apple-system, " font-size:14px;white-space:normal;background-color:#ffffff;"="">?</span></span></sup><span style="font-family:Verdana;">) or generic products but no data exist concerning the differences in treatment outcomes between these products. </span><b><span style="font-family:Verdana;">Methods and Results: </span></b><span style="font-family:Verdana;">We investigated the differences in the serum levels of EPA, docosahexaenoic acid (DHA) and arachidonic acid (AA), and the EPA/AA ratios through blood sampling six months after daily administration of 1800 mg of EPADEL</span><sup><span style="font-family:Verdana;"><span style="color:#4F4F4F;font-family:-apple-system, " font-size:14px;white-space:normal;background-color:#ffffff;"="">?</span></span></sup><span style="font-family:Verdana;"> and a generic EPA drug was initiated for 96 patients with cardiovascular diseases. All patients received these PUFA treatments while continuing with baseline therapy. After 6 months of administration, EPADEL</span><sup><span style="font-family:Verdana;"><span style="color:#4F4F4F;font-family:-apple-system, " font-size:14px;white-space:normal;background-color:#ffffff;"="">?</span></span></sup><span style="font-family:Verdana;"> produced better results than the generic (G) product (EPA;baseline: 59.4 ± 25.5 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B: 215.5 ± 58.8 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, G: 199.7 ± 63.8 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B vs G, p < 0.0005;AA;baseline: 197.4 ± 44.6 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B: 158.3 ± 36.3 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, G: 163.6 ± 38.9 </span><span style="font-family:Verdana;">μ</span><span style="font-family:Verdana;">g, B vs G, p < 0.02, as mean ± SD). </span><b><span style="font-family:Verdana;">Conclusions</span></b></span><b><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> There were clear differences between EPA branded and the generic products. Further study is required to determine whether the benefits from the branded product justify the higher price compared to the generic drug cost.</span>
